Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Moving CAR-T to earlier lines of therapy in children and young adults with B-ALL

Shannon Maude • 30 May 2026
ASCO 2026
Acute Lymphoblastic Leukemia Leukemia CAR-T

In this video, Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, briefly discusses the importance of studying CAR T-cell therapy in earlier lines of therapy in pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL), as with standard therapy, the risk of subsequent relapse remains high. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shannon Maude

Tisa-cel in pediatric & young adult patients with HR B-ALL and MRD after frontline consolidation
1:37
Tisa-cel in pediatric & young adult patients with HR B-ALL and MRD after frontline consolidation
Shannon Maude • 30 May 2026
The future of CAR-T therapy in ALL
11:16
The future of CAR-T therapy in ALL
Bijal Shah et al. • 30 Apr 2022
Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL
7:19
Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL
Shannon Maude • 3 Dec 2018

Related Videos

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
36:40
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
Anna Schuh et al. • 20 Mar 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
Fixed-duration versus continuous therapy in CLL: clinical considerations, the CLL17 trial, & more
25:26
Fixed-duration versus continuous therapy in CLL: clinical considerations, the CLL17 trial, & more
Alessandra Tedeschi et al. • 11 May 2026
BTK inhibitors in CLL: sequencing, combinations, and advice for the community
33:32
BTK inhibitors in CLL: sequencing, combinations, and advice for the community
Jennifer Woyach et al. • 27 Apr 2026
The content of VJHemOnc is intended for healthcare professionals